Jane Thomas-Oates

Dr. Jane Thomas-Oates

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Water Research
Verified
Journal Article
Closed access
EBEmily E. Burns
Emily E. Burns
LCLaura J. Carter
Laura J. Carter
DKDana W. Kolpin
Dana W. Kolpin
JTJane Thomas-Oates
Jane Thomas-Oates
ABAlistair B.A. Boxall
Alistair B.A. Boxall

3 April 2018 in Journal of Toxicology and Environmental Health, Part B
Verified
Journal Article
Closed access
EBEmily E. Burns
Emily E. Burns
LCLaura J. Carter
Laura J. Carter
JSJason Snape
Jason Snape
JTJane Thomas-Oates
Jane Thomas-Oates
ABAlistair B.A. Boxall
Alistair B.A. Boxall
Pharmaceuticals are ubiquitous in the natural environment with concentrations expected to rise as human population increases. Environmental risk assessments are available for a small portion of pharmaceuticals in use, raising concerns over the potential risks posed by other drugs that have little or no data. With >1900 active pharmaceutical ingredients in use, it would be a major task to test all of the compounds with little or no data. Desk-based prioritization studies provide a potential solution by identifying those substances that are likely to pose the greatest risk to the environment and which, therefore, need to be considered a priority for further study. The aim of this review was to (1) provide an overview of different prioritization exercises performed for pharmaceuticals in the environment and the results obtained; and (2) propose a new holistic risk-based prioritization framework for drugs in the environment. The suggested models to underpin this framework are discussed in terms of validity and applicability. The availability of data required to run the models was assessed and data gaps identified. The implementation of this framework may harmonize pharmaceutical prioritization efforts and ensure that, in the future, experimental resources are focused on molecules, endpoints, and environmental compartments that are biologically relevant.

1 February 1994 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
GBGuido V. Bloemberg
Guido V. Bloemberg
JTJane Thomas-Oates
Jane Thomas-Oates
BLBen J. J. Lugtenberg
Ben J. J. Lugtenberg
Herman SpainkHerman Spaink
Herman Spaink

1 January 2020 in STAR: Science & Technology of Archaeological Research
Verified
Journal Article
Open access
LDLéa Drieu
Léa Drieu
MRMaxime Rageot
Maxime Rageot
NWNathan Wales
Nathan Wales
BSBen Stern
Ben Stern
JLJasmine Lundy
Jasmine Lundy
OCOliver E. Craig
Oliver E. Craig
Chemical analysis of archaeological artefacts is used with increasing regularity to understand how wine was produced, traded, and consumed in the past and to shed light on its antiquity. Based both on an extensive review of the published literature and on new analyses, here we critically evaluate the diverse range of methodological approaches that have been used for wine identification. Overall, we conclude that currently none of the proposed chemical ‘biomarkers’ for wine provide unequivocal evidence. Nevertheless, valid interpretations may be offered if systematically supported by additional contextual data, such as archaeobotanical evidence. We found the extraction and detection method to be particularly crucial for successful identification. We urge the use of controls and quantification to rule out false positives. DNA sequencing offers potential for identifying wine and provides much higher taxonomic resolution, but work is needed to determine the limits of DNA survival on artefacts.

13 August 2019 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PFPeter Fisher
Peter Fisher
JTJane Thomas-Oates
Jane Thomas-Oates
AWA. Jamie Wood
A. Jamie Wood
DUDaniel Ungar
Daniel Ungar
Heterogeneity is an inherent feature of the glycosylation process. Mammalian cells often produce a variety of glycan structures on separate molecules of the same protein, known as glycoforms. This heterogeneity is not completely random but is controlled by the organization of the glycosylation machinery in the Golgi cisternae. In this work, we use a computational model of the N-glycosylation process to probe how the organization of the glycosylation machinery into different cisternae drives N-glycan biosynthesis towards differing degrees of heterogeneity. Using this model, we demonstrate the N-glycosylation potential and limits of the mammalian Golgi apparatus, for example how the number of cisternae limits the goal of achieving near homogeneity for N-glycans. The production of specific glycoforms guided by this study could pave the way for ‘glycoform engineering’, which will find use in the functional investigation of glycans, the modulation of glycan-mediated physiological functions and in biotechnology.

10 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TWTomasz Witkos
Tomasz Witkos
WCWing Lee Chan
Wing Lee Chan
MJMerja Joensuu
Merja Joensuu
MRManuel Rhiel
Manuel Rhiel
EPEd Pallister
Ed Pallister
MLMartin Lowe
Martin Lowe
COPI is a key mediator of protein trafficking within the secretory pathway. COPI is recruited to the membrane primarily through binding to Arf GTPases, upon which it undergoes assembly to form coated transport intermediates responsible for trafficking numerous proteins, including Golgi-resident enzymes. Here, we identify GORAB, the protein mutated in the skin and bone disorder gerodermia osteodysplastica, as a component of the COPI machinery. GORAB forms stable domains at the trans-Golgi that, via interactions with the COPI-binding protein Scyl1, promote COPI recruitment to these domains. Pathogenic GORAB mutations perturb Scyl1 binding or GORAB assembly into domains, indicating the importance of these interactions. Loss of GORAB causes impairment of COPI-mediated retrieval of trans-Golgi enzymes, resulting in a deficit in glycosylation of secretory cargo proteins. Our results therefore identify GORAB as a COPI scaffolding factor, and support the view that defective protein glycosylation is a major disease mechanism in gerodermia osteodysplastica.